이수앱지스
Financials
Valuation Metrics
이수앱지스's Market Cap is ₩1352B. At end of 2025 it was ₩2100B. Ranked #1043 of 2,436 in KR market (top 43%), #526 of 1,649 on KOSDAQ (top 32%), #124 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 135.17B KRW | KR#1,043/2,436 Sec#124/234 |
| Revenue | 58.94B KRW | KR#1,691/2,436 Sec#115/234 |
| Net Income | -2.12B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 153.02B KRW | KR#1,465/2,436 Sec#115/234 |
| Net Assets | 115.42B KRW | KR#1,295/2,436 Sec#103/234 |
| Employees | 190 | KR#1,126/2,436 Sec#93/234 |
| Value | ||
| P/B | 1.17x | KR#1,620/2,436 Sec#110/234 |
| P/S | 2.29x | KR#1,893/2,436 Sec#109/234 |
| FCF Yield | 4.97% | KR#871/2,436 Sec#44/234 |
| Profitability | ||
| ROE | -1.84% | KR#1,606/2,436 Sec#111/234 |
| ROA | -1.38% | KR#1,640/2,436 Sec#116/234 |
| Op. Margin | -2.28% | KR#1,766/2,436 Sec#121/234 |
| Revenue Growth | 31.59% | KR#461/2,436 Sec#41/234 |
| Earnings Growth | -172.55% | KR#1,474/2,436 Sec#96/234 |
| Financial Health | ||
| Debt Ratio | 132.58% | KR#896/2,436 Sec#104/234 |
| Total Debt | 18.08B KRW | KR#1,394/2,436 Sec#116/234 |
| FCF | 6.71B KRW | KR#823/2,436 Sec#53/234 |
| Cash | 17.64B KRW | KR#1,321/2,436 Sec#102/234 |
| Current Ratio | 2.16x | KR#874/2,436 Sec#101/234 |
| Performance | ||
| 1Y Return | -35.38% | KR#1,716/2,436 Sec#151/234 |
| 1M Return | -4.74% | KR#1,372/2,436 Sec#141/234 |
| From 52W High | -47.80% | KR#1,093/2,436 Sec#92/234 |
| 1Y MDD | -52.32% | KR#1,031/2,436 Sec#84/234 |
| Trading | ||
| Volume | 57,683 shares | KR#1,255/2,436 Sec#124/234 |
| Foreign Own. | 2.47% | KR#1,050/2,436 Sec#103/234 |
| Per Share | ||
| EPS | -54 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,831 KRW | KR#1,850/2,436 Sec#146/234 |
Company Info
Established in 2001, Isu Abxis is a specialized company that develops, manufactures, and sells biotechnology-based therapeutic antibodies and proteins, having been special listed on the KOSDAQ market in 2009. Its key therapeutic products include Abcertin, Pabagal, Clotynap, Feburain, Trientop, and Casavan, and it continues to grow in its unique field. The company is promoting export expansion and market diversification, notably by signing sales right contracts for Pabagal in 11 countries including Russia and Taiwan. Isu Abxis is also reviewing the development of therapeutic products for cancer and intractable diseases and is headquartered in Seongnam-si, Gyeonggi-do.